DE69925009D1 - Lage-spezifische markierung von disulfide-enthaltenden zielgerichteten vektoren - Google Patents

Lage-spezifische markierung von disulfide-enthaltenden zielgerichteten vektoren

Info

Publication number
DE69925009D1
DE69925009D1 DE69925009T DE69925009T DE69925009D1 DE 69925009 D1 DE69925009 D1 DE 69925009D1 DE 69925009 T DE69925009 T DE 69925009T DE 69925009 T DE69925009 T DE 69925009T DE 69925009 D1 DE69925009 D1 DE 69925009D1
Authority
DE
Germany
Prior art keywords
diagnostic
polypeptide
protein
disulfide
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69925009T
Other languages
English (en)
Other versions
DE69925009T2 (de
Inventor
J Mcbride
L Griffiths
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of DE69925009D1 publication Critical patent/DE69925009D1/de
Application granted granted Critical
Publication of DE69925009T2 publication Critical patent/DE69925009T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dicing (AREA)
  • Semiconductor Memories (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
DE69925009T 1998-10-13 1999-10-13 Lage-spezifische markierung von disulfide-enthaltenden zielgerichteten vektoren Expired - Lifetime DE69925009T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10390498P 1998-10-13 1998-10-13
US103904P 1998-10-13
PCT/US1999/023614 WO2000021573A1 (en) 1998-10-13 1999-10-13 Site-specific labeling of disulfide-containing targeting vectors

Publications (2)

Publication Number Publication Date
DE69925009D1 true DE69925009D1 (de) 2005-06-02
DE69925009T2 DE69925009T2 (de) 2006-03-02

Family

ID=22297637

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69925009T Expired - Lifetime DE69925009T2 (de) 1998-10-13 1999-10-13 Lage-spezifische markierung von disulfide-enthaltenden zielgerichteten vektoren

Country Status (8)

Country Link
EP (1) EP1121153B1 (de)
JP (1) JP4680387B2 (de)
AT (1) ATE293996T1 (de)
AU (1) AU755783B2 (de)
CA (1) CA2346170C (de)
DE (1) DE69925009T2 (de)
ES (1) ES2242426T3 (de)
WO (1) WO2000021573A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287149A1 (de) 2009-08-20 2011-02-23 Max-Delbrück-Centrum Für Molekulare Medizin Verstärker des Proteinabbaus
AU2014299561B2 (en) * 2013-06-24 2017-06-08 Ablbio Antibody-drug conjugate having improved stability and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
CA2222966C (en) * 1995-06-07 2007-03-13 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy

Also Published As

Publication number Publication date
CA2346170C (en) 2010-01-12
AU6424499A (en) 2000-05-01
ATE293996T1 (de) 2005-05-15
EP1121153A1 (de) 2001-08-08
JP4680387B2 (ja) 2011-05-11
WO2000021573A1 (en) 2000-04-20
ES2242426T3 (es) 2005-11-01
EP1121153B1 (de) 2005-04-27
AU755783B2 (en) 2002-12-19
DE69925009T2 (de) 2006-03-02
JP2002527409A (ja) 2002-08-27
CA2346170A1 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
Feinstein et al. Conformation of the free and antigen-bound IgM antibody molecules
Südhof et al. Cassette of eight exons shared by genes for LDL receptor and EGF precursor
Niznik et al. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus
ATE353864T1 (de) Fluorierung von proteinen und peptiden für positronemissionstomographie
Niedel et al. Covalent affinity labeling of the formyl peptide chemotactic receptor.
DE69637781D1 (de) Für den il-13 rezeptor spezifische chimäre proteine und ihre verwendungen
BR9713727A (pt) Corpos oleosos e proteìnas associados como matrizes de afinicade.
BR0011849A (pt) Anticorpos enxertados lm609 melhorados
EA200000109A1 (ru) Химерный белок растворимого рецептора интерлейкина-6/лиганда, его аналоги и способы применения
DK1084145T3 (da) Antistoffer imod ED-B-domænet i fibronectin, konjugater indeholdende disse og anvendelse deraf til diagnosticering og behandling af tumorer og sygdomme forbundet med angiogenese
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
EP1590434A4 (de) Mit bauchspeicheldrüsenkrebs assoziiertes antigen, antikörper dagegen sowie diagnose- und behandlungsverfahren
DE69330643D1 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
Yu Studies on the pargyline-binding site of different types of monoamine oxidase
DE69505804D1 (de) Afamin: ein menschliches serum albumin ähnliches protein
DE60041243D1 (de) Gebrauchsverfaheren eines neuen lysyloxidase-verwandten proteins
Watanabe et al. Azidobutyryl clentiazem, a new photoactivatable diltiazem analog, labels benzothiazepine binding sites in the α1 subunit of the skeletal muscle calcium channel
Veijola et al. Co-expression of the α subunit of human prolyl 4-hydroxylase with BiP polypeptide in insect cells leads to the formation of soluble and insoluble complexes. Soluble α-subunit-BiP complexes have no prolyl 4-hydroxylase activity
DE69841322D1 (de) Hepatitis c rezeptorprotein cd81
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
PT85317A (fr) Procede pour l:obtention d:imunotoxines par couplage d:un anticorps avec une proteine trichosanthine ou trickokirine
ATE364627T1 (de) G-protein gekoppelter rezeptor mit vergrösserter, extrazellulärer domäne
ES2106890T3 (es) Antigeno linfoide cd30.
DE69925009D1 (de) Lage-spezifische markierung von disulfide-enthaltenden zielgerichteten vektoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition